Fourth‐line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures
Open Access
- 28 February 2012
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 35 (8) , 941-947
Abstract
Summary: Background: In some cases, Helicobacter pylori infection persists even after three eradication treatments.Aim: To evaluate the efficacy of an empirical fourth‐line rescue regimen with rifabutin in patients with three eradication failures.Methods: Design: Multicentre, prospective study. Patients: In whom the following three treatments had consecutively failed: first (PPI + clarithromycin + amoxicillin); second (PPI + bismuth + tetracycline + metronidazole); third (PPI + amoxicillin + levofloxacin). Intervention: A fourth regimen with rifabutin (150 mg b.d.), amoxicillin (1 g b.d.) and a PPI (standard dose b.d.) was prescribed for 10 days. Outcome: Eradication was confirmed by 13C‐urea breath test 4–8 weeks after therapy. Compliance and tolerance: Compliance was determined through questioning and recovery of empty medication envelopes. Adverse effects were evaluated using a questionnaire.Results: One‐hundred patients (mean age 50 years, 39% men, 31% peptic ulcer/69% functional dyspepsia) were included. Eight patients did not take the medication correctly (in six cases due to adverse effects). Per‐protocol and intention‐to‐treat eradication rates were 52% (95% CI = 41–63%) and 50% (40–60%). Adverse effects were reported in 30 (30%) patients: nausea/vomiting (13 patients), asthenia/anorexia (8), abdominal pain (7), diarrhoea (5), fever (4), metallic taste (4), myalgia (4), hypertransaminasemia (2), leucopenia (H. pylori eradication failures, an empirical fourth‐line rescue treatment with rifabutin may be effective in approximately 50% of the cases. Therefore, rifabutin‐based rescue therapy constitutes a valid strategy after multiple previous eradication failures with key antibiotics, such as clarithromycin, metronidazole, tetracycline and levofloxacin.Keywords
This publication has 39 references indexed in Scilit:
- Helicobacter pyloriInfectionNew England Journal of Medicine, 2010
- Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate helicobacter pylori infectionBMC Gastroenterology, 2007
- Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus ReportGut, 2007
- Efficacy and safety of rifabutin‐containing ‘rescue therapy’ for resistant Helicobacter pylori infectionAlimentary Pharmacology & Therapeutics, 2006
- Systematic review and meta‐analysis: levofloxacin‐based rescue regimens after Helicobacter pylori treatment failureAlimentary Pharmacology & Therapeutics, 2005
- Rifabutin‐ and furazolidone‐based Helicobacter pylori eradication therapies after failure of standard first‐ and second‐line eradication attempts in dyspepsia patientsAlimentary Pharmacology & Therapeutics, 2004
- Basis for the Management of Drug-Resistant Helicobacter pylori InfectionDrugs, 2004
- In Vitro Activity of Clarithromycin against Intracellular Helicobacter pyloriAntimicrobial Agents and Chemotherapy, 2001
- Antimicrobial Activity of RifabutinClinical Infectious Diseases, 1996
- RifabutinDrugs, 1994